



Clinical trial results:

A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lots and a High Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults

Summary

EudraCT number	2015-001658-14
Trial protocol	ES
Global end of trial date	29 September 2017

Results information

Result version number	v2 (current)
This version publication date	14 November 2018
First version publication date	26 September 2018
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	V920-012
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02503202
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 September 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	29 September 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The study evaluated the safety and immunogenicity of 3 consistency lots and a high-dose lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in healthy adults. The primary purpose of this study was to demonstrate consistency in the immune responses of participants receiving 3 separate lots of V920 through 28 days postvaccination. In addition to the 3 lot groups, a high-dose group and a placebo group were studied. A subset of participants representative of all treatment groups continued through 24 months postvaccination in the extension study for the evaluation of long-term safety. The primary hypothesis states that the geometric mean titer of anti-Zaire ebolavirus envelope (ZEBOV) glycoprotein antibody at 28 days postvaccination is equivalent across the three consistency lots.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	17 August 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 24
Country: Number of subjects enrolled	Spain: 40
Country: Number of subjects enrolled	United States: 1133
Worldwide total number of subjects	1197
EEA total number of subjects	40

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1186
From 65 to 84 years	11
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study enrolled healthy male and female adults.

Pre-assignment

Screening details:

A total of 1261 participants were screened and 1197 were randomized.

Period 1

Period 1 title	Base Study: Up to Month 6
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Assessor

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	V920 Consistency Lot A
------------------	------------------------

Arm description:

Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1

Arm type	Experimental
Investigational medicinal product name	V920 Consistency Lot A
Investigational medicinal product code	
Other name	V920 (rVSVZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Nominal $\geq 2 \times 10^7$ plaque-forming units in 1 mL for intramuscular injection

Arm title	V920 Consistency Lot B
------------------	------------------------

Arm description:

Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1

Arm type	Experimental
Investigational medicinal product name	V920 Consistency Lot B
Investigational medicinal product code	
Other name	V920 (rVSVZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Nominal $\geq 2 \times 10^7$ plaque-forming units in 1 mL for intramuscular injection

Arm title	V920 Consistency Lot C
------------------	------------------------

Arm description:

Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1

Arm type	Experimental
----------	--------------

Investigational medicinal product name	V920 Consistency Lot C
Investigational medicinal product code	
Other name	V920 (rVSVZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Nominal $\geq 2 \times 10^7$ plaque-forming units in 1 mL for intramuscular injection	
Arm title	V920 High-dose Lot
Arm description:	
Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1	
Arm type	Experimental
Investigational medicinal product name	V920 High-dose Lot
Investigational medicinal product code	
Other name	V920 (rVSVZEBOV-GP) Ebola Zaire vaccine consistency high-dose lot, live, attenuated, sterile solution for intramuscular injection
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Nominal $\geq 1 \times 10^8$ plaque-forming units in 1 mL for intramuscular injection	
Arm title	Placebo
Arm description:	
Participants received a 1.0-mL intramuscular injection of placebo on Day 1	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	Normal saline (0.9%)
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details:	
1 mL for intramuscular injection	

Number of subjects in period 1	V920 Consistency Lot A	V920 Consistency Lot B	V920 Consistency Lot C
Started	266	265	267
Vaccinated	266	265	266
Completed	248	253	252
Not completed	18	12	15
Adverse event, serious fatal	1	1	-
Consent withdrawn by subject	6	3	4
Physician decision	-	-	-
Randomized not vaccinated	-	-	1
Lost to follow-up	11	8	10

Number of subjects in period 1	V920 High-dose Lot	Placebo
Started	266	133

Vaccinated	264	133
Completed	255	130
Not completed	11	3
Adverse event, serious fatal	-	-
Consent withdrawn by subject	4	1
Physician decision	-	1
Randomized not vaccinated	2	-
Lost to follow-up	5	1

Period 2

Period 2 title	Extension: Month 6 to 24
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	V920 Consistency Lot A

Arm description:

Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No vaccine was administered in the study extension.

Arm type	Experimental
Investigational medicinal product name	V920 Consistency Lot A
Investigational medicinal product code	
Other name	V920 (rVSVZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Nominal $\geq 2 \times 10^7$ plaque-forming units in 1 mL for intramuscular injection on Day 1 in the Base Study. No vaccine was administered in the study extension.

Arm title	V920 Consistency Lot B
------------------	------------------------

Arm description:

Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No vaccine was administered in the study extension.

Arm type	Experimental
Investigational medicinal product name	V920 Consistency Lot B
Investigational medicinal product code	
Other name	V920 (rVSVZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Nominal $\geq 2 \times 10^7$ plaque-forming units in 1 mL for intramuscular injection on Day 1 in the Base Study. No vaccine was administered in the study extension.

Arm title	V920 Consistency Lot C
Arm description: Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No vaccine was administered in the study extension.	
Arm type	Experimental
Investigational medicinal product name	V920 Consistency Lot C
Investigational medicinal product code	
Other name	V920 (rVSVZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details: Nominal $\geq 2 \times 10^7$ plaque-forming units in 1 mL for intramuscular injection on Day 1 in the Base Study. No vaccine was administered in the study extension.	
Arm title	V920 High-dose Lot
Arm description: Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No vaccine was administered in the study extension.	
Arm type	Experimental
Investigational medicinal product name	V920 High-dose Lot
Investigational medicinal product code	
Other name	V920 (rVSVZEBOV-GP) Ebola Zaire vaccine consistency high-dose lot, live, attenuated, sterile solution for intramuscular injection
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details: Nominal $\geq 1 \times 10^8$ plaque-forming units in 1 mL for intramuscular injection on Day 1 in the Base Study. No vaccine was administered in the study extension.	
Arm title	Placebo
Arm description: Participants received a 1.0-mL intramuscular injection of placebo on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No vaccine was administered in the study extension.	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	Normal saline (0.9%)
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details: 1 mL for intramuscular injection on Day 1 in the Base Study. No placebo was administered in the study extension.	

Number of subjects in period 2^[1]	V920 Consistency Lot A	V920 Consistency Lot B	V920 Consistency Lot C
Started	119	130	112
Completed	108	114	103
Not completed	11	16	9
Adverse event, serious fatal	1	-	-
Physician decision	1	-	1
Consent withdrawn by subject	5	8	2
Lost to follow-up	4	8	6
Protocol deviation	-	-	-

Number of subjects in period 2^[1]	V920 High-dose Lot	Placebo
Started	137	68
Completed	119	67
Not completed	18	1
Adverse event, serious fatal	-	-
Physician decision	3	-
Consent withdrawn by subject	4	-
Lost to follow-up	10	1
Protocol deviation	1	-

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Participants from selected US sites were invited to enroll in the study extension. Participation in the study extension was voluntary.

Baseline characteristics

Reporting groups

Reporting group title	V920 Consistency Lot A
Reporting group description:	
Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1	
Reporting group title	V920 Consistency Lot B
Reporting group description:	
Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1	
Reporting group title	V920 Consistency Lot C
Reporting group description:	
Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1	
Reporting group title	V920 High-dose Lot
Reporting group description:	
Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1	
Reporting group title	Placebo
Reporting group description:	
Participants received a 1.0-mL intramuscular injection of placebo on Day 1	

Reporting group values	V920 Consistency Lot A	V920 Consistency Lot B	V920 Consistency Lot C
Number of subjects	266	265	267
Age categorical			
Units: Subjects			
Adults (18-64 years)	263	263	263
From 65-84 years	3	2	4
Age Continuous			
Units: Years			
arithmetic mean	41.3	41.5	40.9
standard deviation	± 13.4	± 12.4	± 13.1
Sex: Female, Male			
Units: Subjects			
Female	143	135	138
Male	123	130	129

Reporting group values	V920 High-dose Lot	Placebo	Total
Number of subjects	266	133	1197
Age categorical			
Units: Subjects			
Adults (18-64 years)	265	132	1186
From 65-84 years	1	1	11
Age Continuous			
Units: Years			
arithmetic mean	41.7	41.1	-
standard deviation	± 13.4	± 13.7	-
Sex: Female, Male			
Units: Subjects			
Female	149	72	637
Male	117	61	560

End points

End points reporting groups

Reporting group title	V920 Consistency Lot A
Reporting group description: Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1	
Reporting group title	V920 Consistency Lot B
Reporting group description: Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1	
Reporting group title	V920 Consistency Lot C
Reporting group description: Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1	
Reporting group title	V920 High-dose Lot
Reporting group description: Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1	
Reporting group title	Placebo
Reporting group description: Participants received a 1.0-mL intramuscular injection of placebo on Day 1	
Reporting group title	V920 Consistency Lot A
Reporting group description: Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No vaccine was administered in the study extension.	
Reporting group title	V920 Consistency Lot B
Reporting group description: Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No vaccine was administered in the study extension.	
Reporting group title	V920 Consistency Lot C
Reporting group description: Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No vaccine was administered in the study extension.	
Reporting group title	V920 High-dose Lot
Reporting group description: Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No vaccine was administered in the study extension.	
Reporting group title	Placebo
Reporting group description: Participants received a 1.0-mL intramuscular injection of placebo on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No vaccine was administered in the study extension.	

Primary: Geometric Mean Titer of Anti-ZEBOV Glycoprotein Antibody

End point title	Geometric Mean Titer of Anti-ZEBOV Glycoprotein Antibody
End point description: Serum was collected for determination of geometric mean titer (GMT) of anti-Zaire ebolavirus envelope (ZEBOV) glycoprotein antibodies using an enzyme-linked immunosorbent assay (GP-ELISA). The unit of measure is ELISA units/mL (EU/mL). The lower limit of quantification for the assay was 36.11 EU/mL. A value of 36.11 in the table means that the geometric mean and CIs were <36.11 EU/mL. The population analyzed was participants who were compliant with the protocol, received vaccination, were seronegative at Day 1, and had a serum sample collected within the acceptable day range.	

End point type	Primary
End point timeframe:	
Day 28 postvaccination	

End point values	V920 Consistency Lot A	V920 Consistency Lot B	V920 Consistency Lot C	V920 High-dose Lot
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	239	231	226	219
Units: EU/mL				
geometric mean (confidence interval 95%)	1183.9 (1038.7 to 1349.4)	1266.0 (1108.2 to 1446.2)	1346.0 (1176.6 to 1539.9)	1291.9 (1126.9 to 1481.2)

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	124			
Units: EU/mL				
geometric mean (confidence interval 95%)	36.11 (36.11 to 36.11)			

Statistical analyses

Statistical analysis title	Equivalence
Comparison groups	V920 Consistency Lot B v V920 Consistency Lot A
Number of subjects included in analysis	470
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[1]
Method	ANOVA
Parameter estimate	GMT ratio (Lot A / Lot B)
Point estimate	0.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.77
upper limit	1.14

Notes:

[1] - Primary analysis: a p-value <0.025 supported the conclusion of equivalence. If equivalence was established for the 3 pairwise comparisons, the lots would be considered to be consistent.

Statistical analysis title	Equivalence
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot C

Number of subjects included in analysis	465
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[2]
Method	ANOVA
Parameter estimate	GMT ratio (Lot A / Lot C)
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.71
upper limit	1.09

Notes:

[2] - Primary analysis: a p-value <0.025 supported the conclusion of equivalence. If equivalence was established for the 3 pairwise comparisons, the lots would be considered to be consistent.

Statistical analysis title	Equivalence
Comparison groups	V920 Consistency Lot B v V920 Consistency Lot C
Number of subjects included in analysis	457
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001 ^[3]
Method	ANOVA
Parameter estimate	GMT ratio (Lot B / Lot C)
Point estimate	0.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.77
upper limit	1.15

Notes:

[3] - Primary analysis: a p-value <0.025 supported the conclusion of equivalence. If equivalence was established for the 3 pairwise comparisons, the lots would be considered to be consistent.

Primary: Percentage of Participants Reporting Serious Adverse Events

End point title	Percentage of Participants Reporting Serious Adverse Events
End point description:	
An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. A serious AE (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is any other important medical event, is a cancer, or is associated with an overdose. The population analyzed was randomized participants who received vaccination and had follow-up data for the outcome measure.	
End point type	Primary
End point timeframe:	
Up to Month 6 postvaccination	

End point values	V920 Consistency Lot A	V920 Consistency Lot B	V920 Consistency Lot C	V920 High-dose Lot
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	265	263	263	260
Units: Percentage of participants				
number (not applicable)	2.6	1.5	2.7	1.2

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	133			
Units: Percentage of participants				
number (not applicable)	0.0			

Statistical analyses

Statistical analysis title	Risk Difference
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot B
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.368
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	4

Statistical analysis title	Risk Difference
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot C
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.989
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	0

Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.1
upper limit	3

Statistical analysis title	Risk Difference
Comparison groups	V920 Consistency Lot B v V920 Consistency Lot C
Number of subjects included in analysis	526
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.361
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.1
upper limit	1.5

Statistical analysis title	Risk Difference
Comparison groups	V920 High-dose Lot v Placebo
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.214
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	3.3

Primary: Percentage of Participants with Injection-site Adverse Events Prompted on the Vaccination Report Card

End point title	Percentage of Participants with Injection-site Adverse Events Prompted on the Vaccination Report Card
-----------------	---

End point description:

An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or

protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling. The population analyzed was randomized participants who received vaccination and had follow-up data for the outcome measure.

End point type	Primary
End point timeframe:	
Up to Day 5 postvaccination	

End point values	V920 Consistency Lot A	V920 Consistency Lot B	V920 Consistency Lot C	V920 High-dose Lot
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	265	263	263	260
Units: Percentage of participants				
number (not applicable)				
Injection-site erythema	14.7	10.6	14.8	7.3
Injection-site pain	66.8	73.0	70.3	67.7
Injection-site swelling	17.7	13.7	18.3	16.2

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	133			
Units: Percentage of participants				
number (not applicable)				
Injection-site erythema	1.5			
Injection-site pain	12.8			
Injection-site swelling	3.0			

Statistical analyses

Statistical analysis title	Risk Difference
Statistical analysis description:	
Injection site erythema	
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot B
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.16
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	4.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	9.9

Statistical analysis title	Risk Difference
Statistical analysis description:	
Injection site erythema	
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot C
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.971
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.2
upper limit	6

Statistical analysis title	Risk Difference
Statistical analysis description:	
Injection site erythema	
Comparison groups	V920 Consistency Lot B v V920 Consistency Lot C
Number of subjects included in analysis	526
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.151
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	-4.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10
upper limit	1.5

Statistical analysis title	Risk Difference
Statistical analysis description:	
Injection site erythema	
Comparison groups	V920 High-dose Lot v Placebo

Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.016
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	5.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.4
upper limit	9.9

Statistical analysis title	Risk Difference
Statistical analysis description:	
Injection site pain	
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot B
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.12
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	-6.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14
upper limit	1.6

Statistical analysis title	Risk Difference
Statistical analysis description:	
Injection site pain	
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot C
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.38
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	-3.5
Confidence interval	
level	Other: 94 %
sides	2-sided
lower limit	-11.4
upper limit	4.4

Statistical analysis title	Risk Difference
Statistical analysis description:	
Injection site pain	
Comparison groups	V920 Consistency Lot B v V920 Consistency Lot C
Number of subjects included in analysis	526
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.499
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	2.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.1
upper limit	10.4

Statistical analysis title	Risk Difference
Statistical analysis description:	
Injection site pain	
Comparison groups	V920 High-dose Lot v Placebo
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	54.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	46.2
upper limit	62.3

Statistical analysis title	Risk Difference
Statistical analysis description:	
Injection site swelling	
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot B

Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.202
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	10.3

Statistical analysis title	Risk Difference
Statistical analysis description:	
Injection site swelling	
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot C
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.878
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.1
upper limit	6.1

Statistical analysis title	Risk Difference
Statistical analysis description:	
Injection site swelling	
Comparison groups	V920 Consistency Lot B v V920 Consistency Lot C
Number of subjects included in analysis	526
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.154
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	-4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.9
upper limit	1.7

Statistical analysis title	Risk Difference
Statistical analysis description:	
Injection site swelling	
Comparison groups	V920 High-dose Lot v Placebo
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	13.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.4
upper limit	18.6

Primary: Percentage of Participants with Elevated Maximum Temperature

End point title	Percentage of Participants with Elevated Maximum Temperature
End point description:	
Participants were instructed on the VRC to take and record their oral (or oral equivalent) temperature daily from the day of vaccination through Day 42. Elevated temperature was defined as $\geq 38.0^{\circ}\text{C}$ ($\geq 100.4^{\circ}\text{F}$). The population analyzed was randomized participants who received vaccination and had follow-up data for the outcome measure.	
End point type	Primary
End point timeframe:	
Up to Day 42 postvaccination	

End point values	V920 Consistency Lot A	V920 Consistency Lot B	V920 Consistency Lot C	V920 High-dose Lot
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	262	263	263	258
Units: Percentage of participants				
number (not applicable)	21.4	16.7	22.4	32.2

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	132			
Units: Percentage of participants				

number (not applicable)	0.8			
-------------------------	-----	--	--	--

Statistical analyses

Statistical analysis title	Risk Difference
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot B
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.176
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	11.4

Statistical analysis title	Risk Difference
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot C
Number of subjects included in analysis	525
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.769
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.2
upper limit	6

Statistical analysis title	Risk Difference
Comparison groups	V920 Consistency Lot B v V920 Consistency Lot C

Number of subjects included in analysis	526
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.1
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	-5.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.5
upper limit	1.1

Statistical analysis title	Risk Difference
Comparison groups	V920 High-dose Lot v Placebo
Number of subjects included in analysis	390
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	31.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	25.6
upper limit	37.5

Primary: Percentage of Participants with Arthralgia or Arthritis Adverse Events Prompted on the Vaccination Report Card

End point title	Percentage of Participants with Arthralgia or Arthritis Adverse Events Prompted on the Vaccination Report Card
-----------------	--

End point description:

An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Adverse events of arthralgia and arthritis were prompted on the VRC. The population analyzed was randomized participants who received vaccination and had follow-up data for the outcome measure.

End point type	Primary
----------------	---------

End point timeframe:

From Day 5 to Day 42 postvaccination

End point values	V920 Consistency Lot A	V920 Consistency Lot B	V920 Consistency Lot C	V920 High-dose Lot
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	265	263	263	260
Units: Percentage of participants				
number (not applicable)				
Arthralgia AEs	5.7	5.7	6.5	7.7
Arthritis AEs	4.5	3.8	2.7	3.1

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	133			
Units: Percentage of participants				
number (not applicable)				
Arthralgia AEs	1.5			
Arthritis AEs	0.0			

Statistical analyses

Statistical analysis title	Risk Difference
Statistical analysis description: Arthralgia	
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot B
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.983
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.2
upper limit	4.1

Statistical analysis title	Risk Difference
Statistical analysis description: Arthralgia	
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot C

Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.699
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.1
upper limit	3.4

Statistical analysis title	Risk Difference
Statistical analysis description:	
Arthralgia	
Comparison groups	V920 Consistency Lot B v V920 Consistency Lot C
Number of subjects included in analysis	526
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.716
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.1
upper limit	3.5

Statistical analysis title	Risk Difference
Statistical analysis description:	
Arthralgia	
Comparison groups	V920 High-dose Lot v Placebo
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.012
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	6.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.8
upper limit	10.4

Statistical analysis title	Risk Difference
Statistical analysis description:	
Arthritis	
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot B
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.677
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.9
upper limit	4.4

Statistical analysis title	Risk Difference
Statistical analysis description:	
Arthritis	
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot C
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.25
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	5.4

Statistical analysis title	Risk Difference
Statistical analysis description:	
Arthritis	
Comparison groups	V920 Consistency Lot B v V920 Consistency Lot C

Number of subjects included in analysis	526
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.46
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	4.5

Statistical analysis title	Risk Difference
Statistical analysis description:	
Arthritis	
Comparison groups	V920 High-dose Lot v Placebo
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.041
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.2
upper limit	6

Primary: Percentage of Participants with Rash Adverse Events Prompted on the Vaccination Report Card	
End point title	Percentage of Participants with Rash Adverse Events Prompted on the Vaccination Report Card
End point description:	
An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Rash AEs prompted on the VRC were petechial rash, purpuric rash, and vesicular-type rash. The analysis population was randomized participants who received vaccination and had follow-up data for the outcome measure.	
End point type	Primary
End point timeframe:	
Up to Day 42 postvaccination	

End point values	V920 Consistency Lot A	V920 Consistency Lot B	V920 Consistency Lot C	V920 High-dose Lot
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	265	263	263	260
Units: Percentage of participants				
number (not applicable)	3.0	4.6	3.8	3.8

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	133			
Units: Percentage of participants				
number (not applicable)	1.5			

Statistical analyses

Statistical analysis title	Risk Difference
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot B
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.353
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	-1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.1
upper limit	1.9

Statistical analysis title	Risk Difference
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot C
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.62
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	-0.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.2
upper limit	2.5

Statistical analysis title	Risk Difference
Comparison groups	V920 Consistency Lot B v V920 Consistency Lot C
Number of subjects included in analysis	526
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.663
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.9
upper limit	4.5

Statistical analysis title	Risk Difference
Comparison groups	V920 High-dose Lot v Placebo
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.202
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.8
upper limit	5.7

Primary: Percentage of Participants with Vesicular Lesion Adverse Events Prompted on the Vaccination Report Card

End point title	Percentage of Participants with Vesicular Lesion Adverse Events Prompted on the Vaccination Report Card
-----------------	---

End point description:

An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or

protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Vesicular lesion AEs prompted on the VRC included blister and rash vesicular. The population analyzed was randomized participants who received vaccination and had follow-up data for the outcome measure.

End point type	Primary
End point timeframe:	
Up to Day 42 postvaccination	

End point values	V920 Consistency Lot A	V920 Consistency Lot B	V920 Consistency Lot C	V920 High-dose Lot
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	265	263	263	260
Units: Percentage of participants				
number (not applicable)	1.9	1.1	1.5	1.5

End point values	Placebo			
Subject group type	Reporting group			
Number of subjects analysed	133			
Units: Percentage of participants				
number (not applicable)	0.0			

Statistical analyses

Statistical analysis title	Risk Difference
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot B
Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.483
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	3.3

Statistical analysis title	Risk Difference
Comparison groups	V920 Consistency Lot A v V920 Consistency Lot C

Number of subjects included in analysis	528
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.746
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	3

Statistical analysis title	Risk Difference
Comparison groups	V920 Consistency Lot B v V920 Consistency Lot C
Number of subjects included in analysis	526
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.704
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	2

Statistical analysis title	Risk Difference
Comparison groups	V920 High-dose Lot v Placebo
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.151
Method	Miettinen & Nurminen
Parameter estimate	Risk difference (RD)
Point estimate	1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	3.9

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to Month 24

Adverse event reporting additional description:

The at-risk population was randomized participants who received vaccination and had follow-up safety data available.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

Reporting groups

Reporting group title	V920 Lot A
-----------------------	------------

Reporting group description:

Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No vaccine was administered in the study extension.

Reporting group title	V920 Lot B
-----------------------	------------

Reporting group description:

Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No vaccine was administered in the study extension.

Reporting group title	V920 Lot C
-----------------------	------------

Reporting group description:

Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No vaccine was administered in the study extension.

Reporting group title	V920 High Dose
-----------------------	----------------

Reporting group description:

Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No vaccine was administered in the study extension.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received a 1.0-mL intramuscular injection of placebo A on Day 1. A subset of participants was followed beyond Month 6 through approximately Month 24 to assess long-term safety. No placebo was administered in the study extension.

Serious adverse events	V920 Lot A	V920 Lot B	V920 Lot C
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 265 (4.53%)	12 / 263 (4.56%)	11 / 263 (4.18%)
number of deaths (all causes)	2	1	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			

subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	1 / 263 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer stage III			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal squamous cell carcinoma			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	1 / 265 (0.38%)	1 / 263 (0.38%)	1 / 263 (0.38%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ruptured ectopic pregnancy			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Reproductive system and breast disorders			
Menometrorrhagia			
subjects affected / exposed	0 / 265 (0.00%)	1 / 263 (0.38%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	1 / 263 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	1 / 263 (0.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Schizophrenia			

subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Platelet count decreased			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Animal bite			
subjects affected / exposed	0 / 265 (0.00%)	1 / 263 (0.38%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthropod bite			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	1 / 263 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Craniocerebral injury			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Road traffic accident			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Scapula fracture			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Migraine			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radicular pain			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Conductive deafness			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	1 / 263 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal incarcerated hernia			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	1 / 263 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			

subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated umbilical hernia			
subjects affected / exposed	0 / 265 (0.00%)	1 / 263 (0.38%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	1 / 263 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	1 / 265 (0.38%)	1 / 263 (0.38%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 265 (0.00%)	1 / 263 (0.38%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 265 (0.00%)	1 / 263 (0.38%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Endocrine disorders			
Autoimmune thyroiditis			
subjects affected / exposed	0 / 265 (0.00%)	1 / 263 (0.38%)	1 / 263 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthyroidism			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 265 (0.00%)	1 / 263 (0.38%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Exostosis			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
subjects affected / exposed	0 / 265 (0.00%)	1 / 263 (0.38%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	1 / 263 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal column stenosis			
subjects affected / exposed	0 / 265 (0.00%)	1 / 263 (0.38%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			

subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	1 / 263 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	1 / 263 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mastitis			
subjects affected / exposed	0 / 265 (0.00%)	1 / 263 (0.38%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis aseptic			
subjects affected / exposed	0 / 265 (0.00%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 265 (0.38%)	0 / 263 (0.00%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			

subjects affected / exposed	0 / 265 (0.00%)	1 / 263 (0.38%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyperglycaemic hyperosmolar nonketotic syndrome			
subjects affected / exposed	0 / 265 (0.00%)	1 / 263 (0.38%)	0 / 263 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	V920 High Dose	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 260 (3.08%)	4 / 133 (3.01%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	1 / 260 (0.38%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	1 / 260 (0.38%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer stage III			
subjects affected / exposed	0 / 260 (0.00%)	1 / 133 (0.75%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oropharyngeal squamous cell carcinoma			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Deep vein thrombosis			

subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 260 (0.00%)	1 / 133 (0.75%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ruptured ectopic pregnancy			
subjects affected / exposed	1 / 260 (0.38%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Menometrorrhagia			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemothorax			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			

subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	0 / 260 (0.00%)	1 / 133 (0.75%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Schizophrenia			
subjects affected / exposed	1 / 260 (0.38%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal ideation			
subjects affected / exposed	1 / 260 (0.38%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Platelet count decreased			
subjects affected / exposed	0 / 260 (0.00%)	1 / 133 (0.75%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Animal bite			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Arthropod bite			
subjects affected / exposed	0 / 260 (0.00%)	1 / 133 (0.75%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	1 / 260 (0.38%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scapula fracture			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Migraine			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radicular pain			
subjects affected / exposed	1 / 260 (0.38%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			

Conductive deafness			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal incarcerated hernia			
subjects affected / exposed	0 / 260 (0.00%)	1 / 133 (0.75%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorder			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroesophageal reflux disease			
subjects affected / exposed	1 / 260 (0.38%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated umbilical hernia			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic failure			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Skin and subcutaneous tissue disorders Angioedema			
	subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0
Renal and urinary disorders Nephrolithiasis			
	subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0
Renal failure			
	subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0
Endocrine disorders Autoimmune thyroiditis			
	subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0
Hyperthyroidism			
	subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders Back pain			
	subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0
Exostosis			
	subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0
Foot deformity			

subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column stenosis			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mastitis			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis aseptic			

subjects affected / exposed	0 / 260 (0.00%)	1 / 133 (0.75%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hyperglycaemic hyperosmolar nonketotic syndrome			
subjects affected / exposed	0 / 260 (0.00%)	0 / 133 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	V920 Lot A	V920 Lot B	V920 Lot C
Total subjects affected by non-serious adverse events			
subjects affected / exposed	211 / 265 (79.62%)	211 / 263 (80.23%)	208 / 263 (79.09%)
Nervous system disorders			
Headache			
subjects affected / exposed	61 / 265 (23.02%)	51 / 263 (19.39%)	55 / 263 (20.91%)
occurrences (all)	72	56	68
General disorders and administration site conditions			
Chills			
subjects affected / exposed	14 / 265 (5.28%)	16 / 263 (6.08%)	20 / 263 (7.60%)
occurrences (all)	14	16	20

Fatigue			
subjects affected / exposed	21 / 265 (7.92%)	15 / 263 (5.70%)	9 / 263 (3.42%)
occurrences (all)	22	15	9
Influenza like illness			
subjects affected / exposed	14 / 265 (5.28%)	12 / 263 (4.56%)	18 / 263 (6.84%)
occurrences (all)	14	13	19
Injection site erythema			
subjects affected / exposed	39 / 265 (14.72%)	30 / 263 (11.41%)	39 / 263 (14.83%)
occurrences (all)	43	30	42
Injection site pain			
subjects affected / exposed	179 / 265 (67.55%)	192 / 263 (73.00%)	185 / 263 (70.34%)
occurrences (all)	198	215	212
Injection site swelling			
subjects affected / exposed	47 / 265 (17.74%)	36 / 263 (13.69%)	49 / 263 (18.63%)
occurrences (all)	51	40	52
Pain			
subjects affected / exposed	34 / 265 (12.83%)	23 / 263 (8.75%)	29 / 263 (11.03%)
occurrences (all)	34	23	30
Pyrexia			
subjects affected / exposed	58 / 265 (21.89%)	47 / 263 (17.87%)	63 / 263 (23.95%)
occurrences (all)	66	47	70
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	12 / 265 (4.53%)	13 / 263 (4.94%)	15 / 263 (5.70%)
occurrences (all)	12	13	16
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	47 / 265 (17.74%)	41 / 263 (15.59%)	50 / 263 (19.01%)
occurrences (all)	72	74	75
Myalgia			
subjects affected / exposed	17 / 265 (6.42%)	11 / 263 (4.18%)	12 / 263 (4.56%)
occurrences (all)	19	13	12

Non-serious adverse events	V920 High Dose	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	208 / 260 (80.00%)	35 / 133 (26.32%)	

Nervous system disorders			
Headache			
subjects affected / exposed	67 / 260 (25.77%)	15 / 133 (11.28%)	
occurrences (all)	83	18	
General disorders and administration site conditions			
Chills			
subjects affected / exposed	27 / 260 (10.38%)	1 / 133 (0.75%)	
occurrences (all)	27	1	
Fatigue			
subjects affected / exposed	20 / 260 (7.69%)	3 / 133 (2.26%)	
occurrences (all)	21	3	
Influenza like illness			
subjects affected / exposed	9 / 260 (3.46%)	1 / 133 (0.75%)	
occurrences (all)	9	1	
Injection site erythema			
subjects affected / exposed	19 / 260 (7.31%)	2 / 133 (1.50%)	
occurrences (all)	23	2	
Injection site pain			
subjects affected / exposed	176 / 260 (67.69%)	18 / 133 (13.53%)	
occurrences (all)	192	19	
Injection site swelling			
subjects affected / exposed	42 / 260 (16.15%)	4 / 133 (3.01%)	
occurrences (all)	42	4	
Pain			
subjects affected / exposed	32 / 260 (12.31%)	2 / 133 (1.50%)	
occurrences (all)	33	2	
Pyrexia			
subjects affected / exposed	76 / 260 (29.23%)	1 / 133 (0.75%)	
occurrences (all)	83	4	
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	14 / 260 (5.38%)	1 / 133 (0.75%)	
occurrences (all)	15	1	
Musculoskeletal and connective tissue disorders			
Arthralgia			

subjects affected / exposed	53 / 260 (20.38%)	4 / 133 (3.01%)	
occurrences (all)	79	7	
Myalgia			
subjects affected / exposed	23 / 260 (8.85%)	1 / 133 (0.75%)	
occurrences (all)	23	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 July 2015	Amendment 1: Modified Inclusion Criteria to indicate that male subjects of reproductive potential must avoid impregnating a partner for 2 months following study vaccination by complying with the outlined contraception methods.
28 January 2016	Amendment 2: Modified sections to reflect a subset of approximately 600 subjects who will continue in the study through Month 24 in a study extension.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported